Anticoagulant Treatments and Percutaneous Coronary Angioplasty

Coronary Artery Disease Clinical Trial

— TACA  

Official title:

Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00669149
• Other study ID #: CHPAU 2007/01
• Status: Terminated
• Phase: Phase 4
• Start date: June 2008
• Est. completion date: August 3, 2013

Study information

• Verified date: May 2019
• Source: Centre Hospitalier de PAU
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in selected patients.

Description:

• Background : We don't know if using IV anticoagulant therapy is necessary for percutaneous coronary angioplasty in stable patients.

• Purpose : to compare efficacy and security of use or not of different anticoagulant treatments during percutaneous coronary angioplasty in patients with double antiaggregant therapy.

• Abstract : In stable patients pretreated with double antiaggregant therapy use of IV anticoagulants has not been yet evaluated during angioplasty. In this prospective randomized trial we want to compare in such patients the efficacy and security of the administration of IV heparin, IV enoxaparin, IV bivalirudin and no use of anticoagulant during coronary angioplasty. We will evaluate in each group ischaemic events (clinic, ECG and biology) and haemorrhagic events (clinic, biology) with a one month follow up.

• Primary outcome: ischaemic events via troponin Ic measurements during 24 hours post procedure.

• Secondary outcomes: haemorrhagic events : clinical and biological evaluation (Hb, Ht, TIMI score)

• Study design : monocentric randomized clinical trial type therapeutic equivalence phase IV.

• Interventions : In patients prepared with therapeutic association (aspirin clopidogrel) comparison between use or no of anticoagulant (IV heparin, IV enoxaparin or IV bivalirudin).

• Number of subjects : 120 per group (total of 480).

• Statistical analysis : multivariate analysis with logistic regression models : each end point (troponin Ic increase, haemoglobin decrease, …) will be explicated with treatment group and other covariates (sex, age, creatinine, …).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 99
• Est. completion date: August 3, 2013
• Est. primary completion date: August 3, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• stable angina pectoris or silent ischaemia

Exclusion Criteria:

• instable angina or ACS (Acute Coronary Syndrome)

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Drug:
• clopidogrel + aspirin

• heparin + clopidogrel + aspirin

• enoxaparin + clopidogrel + aspirin

• bivalirudin + clopidogrel + aspirin

Locations

Country	Name	City	State
France	Centre Hospitalier de Pau	PAU	Pyrénées-Atlantiques

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier de PAU

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ischaemic events via troponin Ic measurements during 24 hours post procedure		24 hours
Secondary	haemorrhagic events : clinical and biological evaluation		24 hours